Ruxience Injection, Solution
Product Images NDC 0069-0249

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Ruxience (NDC 0069-0249). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Ruxience 01)

A Kaplan-Meier survival curve chart showing progression-free survival probability over time in months for two groups: Observation (n=513) and Rituximab (n=505). The x-axis represents time in months up to 42, and the y-axis shows progression-free survival probability from 0 to 1. The chart includes a table of numbers at risk for each group at various time points. Rituximab is represented by a dashed line and Observation by a solid line.*

FDA Label Image

Figure 2 (Ruxience 02)

A line graph showing the percent of ACR 20 responders over 24 weeks comparing placebo (n=201) and Rituximab 2x1000 mg (n=298). The x-axis represents time in weeks, while the y-axis shows percent responders. Rituximab shows higher response rates over time compared to placebo.*

FDA Label Image

Logo (Ruxience 03)

A survival curve chart comparing percentage of patients with first major relapse over 28 months between treatments Azathioprine and Rituximab. The Y-axis shows the percentage of patients, and the X-axis shows survival time in months. The chart includes subject counts for major relapse and subjects at risk for each treatment over time.*

FDA Label Image

Logo (Ruxience 04)

FDA Label Image

Principal Display Panel (10 mL Vial Label)

FDA Label Image

Principal Display Panel (10 mL Vial Carton)

Ruxience 100 mg/10 mL (rituximab-pvvr) injection label for intravenous use. The single-dose vial contains 10 mL solution at 10 mg/mL strength. The label includes dosage storage instructions, manufacturer Pfizer Ireland Pharmaceuticals, and dispensing information with warnings to discard unused portion.*

FDA Label Image

Principal Display Panel (50 mL Vial Label)

Packaging label for Ruxience (rituximab-pvvr) Injection, 100 mg/10 mL (10 mg/mL) single-dose vial for intravenous use after dilution. The label indicates that the product is a Pfizer Biosimilars product, with instructions to discard unused portions. Storage conditions specify refrigeration at 2°C to 8°C and protection from direct sunlight. Manufactured in Germany by Pfizer Ireland Pharmaceuticals and distributed by Pfizer Labs, Division of Pfizer Inc, New York, NY.*

FDA Label Image

Principal Display Panel (50 mL Vial Carton)

Ruxience (rituximab-pvvr) injection 500 mg/50 mL (10 mg/mL) label for intravenous use. The label includes storage instructions to refrigerate at 2°C to 8°C and protect from light, with warnings against freezing or shaking. It also notes the vial contains no preservative and emphasizes discarding unused portions. Labeler is Pfizer Laboratories Div Pfizer Inc.*

FDA Label Image

Ruxience 09

Packaging label for Ruxience (rituximab-pvvr) 500 mg/50 mL (10 mg/mL) injection, solution for intravenous use. The label indicates it is a single-dose vial to be used after dilution, with instructions to discard unused portions. Manufactured by Pfizer Ireland Pharmaceuticals and distributed by Pfizer Labs, Division of Pfizer Inc. The packaging features the Pfizer Biosimilars logo and includes storage instructions and contents description.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.